FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Heart Failure

Therapeutic area intelligence for Heart Failure with 22 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 22
Catalysts: 0
Companies: 5

Companies

AstraZeneca →

Novo Nordisk →

pharma companies with heart failure portfolios →

Tasly Pharmaceutical →

Torrent Pharmaceuticals →

Assets

Recent signals(22)

ClinicalAugust 1, 2026

Study on ST2 Biomarker for Reducing Heart Failure Readmissions

The study evaluates the prognostic value of ST2 in managing heart failure patients to reduce one-month readmissions.

RegulatoryJuly 31, 2026

Aficamten Approved by MHRA and Recommended by NICE for Heart Condition

Aficamten has received approval from the MHRA and a recommendation from NICE for use in patients with a serious heart condition.

ClinicalJuly 30, 2026

NHLBI Launches MAP-HEART Study to Analyze Heart Failure Phenotypes

The MAP-HEART study aims to collect and analyze biological samples from heart failure patients to identify factors affecting heart function.

ClinicalJuly 28, 2026

Study on IV Iron Therapy for HFpEF Patients with Iron Deficiency Initiated

A new trial is investigating the efficacy of intravenous iron therapy in improving symptoms and quality of life in patients with heart failure with preserved ejection fraction (HFpEF) and iron deficiency.

RegulatoryJuly 28, 2026

FDA Submission Overview for Vericiguat by Torrent Pharmaceuticals

Torrent Pharmaceuticals has submitted an original application for Vericiguat (ANDA220221) to the FDA, currently under standard review.

ClinicalJuly 22, 2026

Metformin Trial Post-LVAD Implantation to Assess Cardiac Function Improvement

A multicenter trial will evaluate the efficacy of metformin in improving cardiac function in LVAD patients over 12 months.

ClinicalJuly 21, 2026

Endotronix Initiates PROACTIVE-HF-2 Trial for Cordella System in Heart Failure Patients

The PROACTIVE-HF-2 trial is evaluating the safety and efficacy of the Cordella Pulmonary Artery Sensor System in patients with NYHA Class II and III heart failure.

ClinicalJuly 20, 2026

Tasly Pharma Trials Qishen Yiqi Pills for Chronic Heart Failure

Tasly Pharmaceutical is conducting a trial to assess the efficacy and safety of Qishen Yiqi Dripping Pills for chronic heart failure with reduced ejection fraction.

ClinicalJuly 17, 2026

Medtronic's Study on Left Bundle Branch Optimized CRT for Heart Failure Outcomes

Medtronic is conducting a feasibility study to evaluate the efficacy of Left Bundle Branch Optimized Cardiac Resynchronization Therapy (LOT-CRT) compared to standard LBBAP in heart failure patients.

ClinicalJuly 14, 2026

AstraZeneca's Dapagliflozin Approved for Heart Failure; Real-World Study Launched in Germany

Dapagliflozin has been approved by the European Commission for heart failure treatment, applicable to all patients regardless of ejection fraction or diabetes status.

ClinicalJuly 8, 2026

Innovative MRI Methods for Characterizing Heart Failure With Preserved Ejection Fraction

A study is underway to develop advanced MRI techniques for assessing microvascular remodeling in HFpEF.

ClinicalJuly 6, 2026

Boston Medical Center Study on Ultrasound for Heart Failure Management

A study is underway to evaluate the effectiveness of a novel ultrasound technique in predicting volume overload in heart failure patients.

StrategyJuly 5, 2026

Torrent Pharmaceuticals submits ANDA for Vericiguat

Torrent Pharmaceuticals has submitted an Abbreviated New Drug Application (ANDA) for Vericiguat.

ClinicalJuly 4, 2026

Pilot Trial on Palliative Care for Advanced Heart Failure Shows Innovative Methodology

A pilot trial is assessing the feasibility and efficacy of a palliative care intervention for older adults with advanced heart failure.

ClinicalJuly 1, 2026

Novo Nordisk's NNC0487-0111 Trial Targets Heart Failure with Obesity

Novo Nordisk is conducting a trial to evaluate the safety and efficacy of NNC0487-0111 in patients with HFpEF or HFmrEF and obesity compared to placebo.

ClinicalJune 28, 2026

Zoll Medical's HFMS Device Trial Aims to Enhance Heart Failure Management Post-Hospitalization

A clinical trial is evaluating the effectiveness of the Heart Failure Management System (HFMS) device in improving patient outcomes after hospitalization for heart failure.

ClinicalJune 22, 2026

Clinical Trial on Video Monitoring for Heart Failure Patients Launched

A randomized clinical trial is assessing the effectiveness of video monitoring versus audio calls for heart failure patients.

ClinicalJune 21, 2026

Dapagliflozin Evaluated for Right Ventricular-Pulmonary Artery Coupling Post-OPCAB

A study is underway to assess the impact of dapagliflozin on right ventricular-pulmonary artery coupling in heart failure patients post-surgery.

ClinicalJune 20, 2026

HEARTFELT Study Evaluates Remote Monitoring Device for Heart Failure Management

The HEARTFELT study is assessing the safety and effectiveness of a remote patient monitoring device for heart failure patients.

ClinicalJune 20, 2026

Yale University Launches Digital Health Initiative for Heart Failure in Uganda

Yale University is implementing a digital-first care model for heart failure in Uganda, evaluating its effectiveness through a cluster-randomized trial.

ClinicalJune 18, 2026

Study on Optimizing CRT Lead Placement for Non-LBBB Patients Using Advanced Imaging Techniques

The RESYNC-PETCT study aims to improve CRT response in heart failure patients with non-LBBB or narrow LBBB patterns through advanced imaging guidance.

ClinicalJune 17, 2026

NORM-HF Study to Evaluate FIRE1 NORM™ System in Heart Failure Management

The NORM-HF study aims to show that the FIRE1 NORM™ System is superior to standard care in managing heart failure.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.